JP2016525135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525135A5 JP2016525135A5 JP2016528479A JP2016528479A JP2016525135A5 JP 2016525135 A5 JP2016525135 A5 JP 2016525135A5 JP 2016528479 A JP2016528479 A JP 2016528479A JP 2016528479 A JP2016528479 A JP 2016528479A JP 2016525135 A5 JP2016525135 A5 JP 2016525135A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- mono
- group
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 oxazolin-2-yl Chemical group 0.000 claims 41
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 27
- 125000004043 oxo group Chemical group O=* 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 239000011737 fluorine Substances 0.000 claims 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 239000000460 chlorine Substances 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 230000003143 atherosclerotic effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical compound FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 239000002583 male contraceptive agent Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- WMWUIOXPIIHGPM-UHFFFAOYSA-N 6-[(1-cyclopentyl-2,4-dimethyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl)amino]-n-cyclopropyl-5-methoxypyridine-3-carboxamide Chemical compound COC1=CC(C(=O)NC2CC2)=CN=C1NC(N=CC=1N(C)C(=O)C2C)=CC=1N2C1CCCC1 WMWUIOXPIIHGPM-UHFFFAOYSA-N 0.000 claims 1
- GNEVURJLYGZTJW-UHFFFAOYSA-N 6-[(1-cyclopentyl-2-ethyl-4-methyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl)amino]-n-cyclopropyl-5-methoxypyridine-3-carboxamide Chemical compound C12=CC(NC=3C(=CC(=CN=3)C(=O)NC3CC3)OC)=NC=C2N(C)C(=O)C(CC)N1C1CCCC1 GNEVURJLYGZTJW-UHFFFAOYSA-N 0.000 claims 1
- WMWUIOXPIIHGPM-CQSZACIVSA-N 6-[[(2r)-1-cyclopentyl-2,4-dimethyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl]amino]-n-cyclopropyl-5-methoxypyridine-3-carboxamide Chemical compound COC1=CC(C(=O)NC2CC2)=CN=C1NC(N=CC=1N(C)C(=O)[C@H]2C)=CC=1N2C1CCCC1 WMWUIOXPIIHGPM-CQSZACIVSA-N 0.000 claims 1
- YGOXHQJLOIZFTN-OAQYLSRUSA-N 6-[[(2r)-1-cyclopentyl-2-ethyl-4-methyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl]amino]-5-methoxy-n-(1-methylpiperidin-4-yl)pyridine-3-carboxamide Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CN=3)C(=O)NC3CCN(C)CC3)OC)C=C21)=O)CC)C1CCCC1 YGOXHQJLOIZFTN-OAQYLSRUSA-N 0.000 claims 1
- MVFMSVWAMWXLJX-MRXNPFEDSA-N 6-[[(2r)-1-cyclopentyl-2-ethyl-4-methyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl]amino]-5-methoxy-n-(2,2,2-trifluoroethyl)pyridine-3-carboxamide Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CN=3)C(=O)NCC(F)(F)F)OC)C=C21)=O)CC)C1CCCC1 MVFMSVWAMWXLJX-MRXNPFEDSA-N 0.000 claims 1
- WSMVHBAXHWEAFQ-GOSISDBHSA-N 6-[[(2r)-1-cyclopentyl-2-ethyl-4-methyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl]amino]-5-methoxy-n-(2-methoxyethyl)pyridine-3-carboxamide Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CN=3)C(=O)NCCOC)OC)C=C21)=O)CC)C1CCCC1 WSMVHBAXHWEAFQ-GOSISDBHSA-N 0.000 claims 1
- GOUNOOFZXRJDCZ-HXUWFJFHSA-N 6-[[(2r)-1-cyclopentyl-2-ethyl-4-methyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl]amino]-5-methoxy-n-(oxan-4-yl)pyridine-3-carboxamide Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CN=3)C(=O)NC3CCOCC3)OC)C=C21)=O)CC)C1CCCC1 GOUNOOFZXRJDCZ-HXUWFJFHSA-N 0.000 claims 1
- GNWCJFXOJSIWHC-OAQYLSRUSA-N 6-[[(2r)-1-cyclopentyl-2-ethyl-4-methyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl]amino]-5-methoxy-n-(pyridin-3-ylmethyl)pyridine-3-carboxamide Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CN=3)C(=O)NCC=3C=NC=CC=3)OC)C=C21)=O)CC)C1CCCC1 GNWCJFXOJSIWHC-OAQYLSRUSA-N 0.000 claims 1
- LOXUGLBNGATOFV-WOJBJXKFSA-N 6-[[(2r)-1-cyclopentyl-2-ethyl-4-methyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl]amino]-5-methoxy-n-[(3r)-2-oxoazepan-3-yl]pyridine-3-carboxamide Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CN=3)C(=O)N[C@H]3C(NCCCC3)=O)OC)C=C21)=O)CC)C1CCCC1 LOXUGLBNGATOFV-WOJBJXKFSA-N 0.000 claims 1
- OQEWSLAUFFCLPV-GOSISDBHSA-N 6-[[(2r)-1-cyclopentyl-2-ethyl-4-methyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl]amino]-n-(1-hydroxy-2-methylpropan-2-yl)-5-methoxypyridine-3-carboxamide Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CN=3)C(=O)NC(C)(C)CO)OC)C=C21)=O)CC)C1CCCC1 OQEWSLAUFFCLPV-GOSISDBHSA-N 0.000 claims 1
- YGMDUKQRUTYKFN-HXUWFJFHSA-N 6-[[(2r)-1-cyclopentyl-2-ethyl-4-methyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl]amino]-n-cyclopropyl-5-ethylpyridine-3-carboxamide Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CN=3)C(=O)NC3CC3)CC)C=C21)=O)CC)C1CCCC1 YGMDUKQRUTYKFN-HXUWFJFHSA-N 0.000 claims 1
- UVIFLSMJSOJWFE-LJQANCHMSA-N 6-[[(2r)-1-cyclopentyl-2-ethyl-4-methyl-3-oxo-2h-pyrido[3,4-b]pyrazin-7-yl]amino]-n-cyclopropyl-5-methylpyridine-3-carboxamide Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CN=3)C(=O)NC3CC3)C)C=C21)=O)CC)C1CCCC1 UVIFLSMJSOJWFE-LJQANCHMSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- IZCYNVGCXPROOK-MRXNPFEDSA-N CC[C@H]1N(C2CCCC2)c2cc(Nc3ncc(cc3C)C(N)=O)ncc2N(C)C1=O Chemical compound CC[C@H]1N(C2CCCC2)c2cc(Nc3ncc(cc3C)C(N)=O)ncc2N(C)C1=O IZCYNVGCXPROOK-MRXNPFEDSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical class 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13177539.7 | 2013-07-23 | ||
| EP13177539 | 2013-07-23 | ||
| PCT/EP2014/065605 WO2015011084A1 (de) | 2013-07-23 | 2014-07-21 | Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525135A JP2016525135A (ja) | 2016-08-22 |
| JP2016525135A5 true JP2016525135A5 (cg-RX-API-DMAC10.html) | 2017-08-31 |
Family
ID=48832802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528479A Withdrawn JP2016525135A (ja) | 2013-07-23 | 2014-07-21 | ＢＥＴタンパク質およびポロ様キナーゼの二重阻害薬としての置換されたジヒドロピリド［３，４−ｂ］ピラジノン類 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160272635A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3027614B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2016525135A (cg-RX-API-DMAC10.html) |
| CN (1) | CN105555786A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2918813A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2648876T3 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1221952A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015011084A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| CN105073744B (zh) | 2012-12-21 | 2019-11-08 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新型杂环化合物 |
| US9636328B2 (en) | 2013-06-21 | 2017-05-02 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN105593224B (zh) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| HK1245247A1 (zh) | 2014-12-17 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| WO2016207345A1 (en) * | 2015-06-24 | 2016-12-29 | Pierre Fabre Medicament | 3-amino-pyrazin-2-yl carboxamide and 2-amino-pyridin-3-yl carboxamide derivatives as polo-like kinase 1 (plk-1) inhibitors for the treatment of cancer |
| WO2017024319A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| KR101796779B1 (ko) | 2015-12-22 | 2017-11-10 | 한국화학연구원 | 다이하이드로프테리딘-온 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| EP3580212A4 (en) | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| CN106977584B (zh) * | 2017-04-19 | 2019-12-06 | 吉林大学 | 靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| WO2018207881A1 (ja) * | 2017-05-12 | 2018-11-15 | 武田薬品工業株式会社 | 複素環化合物 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| CA3095912A1 (en) | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN109096276B (zh) * | 2018-08-01 | 2021-05-28 | 上海博志研新药物技术有限公司 | 盐酸莫西沙星及其中间体的制备方法 |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| CA3165168A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US12527741B2 (en) | 2021-06-17 | 2026-01-20 | Wisconsin Alumni Research Foundation | Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19 |
| CN115947728B (zh) * | 2021-10-09 | 2024-01-09 | 沈阳药科大学 | 含磺酰基的二氢喋啶酮衍生物及其应用 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| CA2578560A1 (en) * | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for the production thereof, and use thereof as a medicament |
| US20110207796A1 (en) * | 2008-02-13 | 2011-08-25 | Elan Pharma International Limited | Alpha-synuclein kinase |
| WO2011143651A1 (en) * | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
| US9249161B2 (en) * | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| JP2015501793A (ja) * | 2011-11-10 | 2015-01-19 | オーエスアイ・ファーマシューティカルズ，エルエルシー | ジヒドロプテリジノン類 |
-
2014
- 2014-07-21 WO PCT/EP2014/065605 patent/WO2015011084A1/de not_active Ceased
- 2014-07-21 US US14/907,367 patent/US20160272635A1/en not_active Abandoned
- 2014-07-21 CN CN201480052256.5A patent/CN105555786A/zh active Pending
- 2014-07-21 EP EP14744029.1A patent/EP3027614B1/de not_active Not-in-force
- 2014-07-21 CA CA2918813A patent/CA2918813A1/en not_active Abandoned
- 2014-07-21 JP JP2016528479A patent/JP2016525135A/ja not_active Withdrawn
- 2014-07-21 ES ES14744029.1T patent/ES2648876T3/es active Active
- 2014-07-21 HK HK16110129.5A patent/HK1221952A1/zh unknown